Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
01 Février 2024 - 2:00PM
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded
with a mission to discover, develop and commercialize innovative,
first-in-class medicines that meet significant unmet medical needs,
today announced it will hold a conference call on Thursday,
February 22, 2024, at 4:30 p.m. Eastern Time to discuss fourth
quarter and full year 2023 financial results and provide a
business update.
To participate in the conference call, please dial (844)
481-2838 (domestic) or (412) 317-1858 (international) and ask to be
joined into the Ardelyx call. Live audio of the conference call
will be simultaneously webcast and will be available under the
Investors section of the company's website
at www.ardelyx.com. The webcast will be archived and
available for replay for 30 days following the call.
About Ardelyx, Inc.Ardelyx was founded with a
mission to discover, develop and commercialize innovative,
first-in-class medicines that meet significant unmet medical needs.
Ardelyx has two commercial products approved in the United States,
IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as
early-stage pipeline candidates. Ardelyx has agreements for the
development and commercialization of tenapanor outside of the U.S.
Kyowa Kirin has received approval for PHOZEVEL® (tenapanor) for
hyperphosphatemia in Japan. A New Drug Application for tenapanor
for hyperphosphatemia has been submitted in China with Fosun
Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For
more information, please visit https://ardelyx.com/ and connect
with us on X (formerly known as Twitter), LinkedIn and
Facebook.
Investor and Media Contacts: Caitlin
Lowieclowie@ardelyx.com
Ardelyx (NASDAQ:ARDX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Ardelyx (NASDAQ:ARDX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024